{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:09:52Z","timestamp":1789610992873,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>EZH2 is a methyltransferase that plays an important tumorigenic role in various neoplasms. We previously found that EZH2 is expressed in a range of aggressive B-cell lymphomas (ABCLs), T-cell lymphomas, and histiocytic neoplasms, with differential expression of intracellular signaling molecules p-ERK, MYC, and p-STAT3, potential regulators of EZH2 expression. We studied EZH2 expression in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), classic Hodgkin lymphoma (cHL), T-cell\/histiocyte-rich large B-cell lymphoma (THRLBCL), and B-cell Lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphomas and classic Hodgkin lymphoma (BCLu-DLBCL\/cHL), as well as the coexpression of p-ERK, MYC, and p-STAT3 in these neoplasms. The neoplastic LP cells of NLPHL and Hodgkin\/Reed-Sternberg cells of cHL were strongly positive for EZH2, as were the neoplastic cells in THRLBCL and BCLu-DLBCL\/cHL. EZH2 expression correlated with proliferation rate, as assessed by Ki-67 staining. LP cells in NLPHL and Hodgkin\/Reed-Sternberg cells in cHL were strongly positive for p-ERK, p-STAT3, and MYC, as were the neoplastic cells in THRLBCL and BCLu-DLBCL\/cHL, in contrast to the differential expression of these molecules seen in ABCLs. These findings suggest that combined expression of p-ERK, MYC, and p-STAT3 is a useful immunohistochemical pattern for the diagnosis of EZH2-positive Hodgkin lymphomas and related lymphomas, in contrast to ABCLs. Furthermore, the overexpression of EZH2, in association with coexpression of tumorigenic signaling molecules, suggests an oncogenic role for this molecule in the development of Hodgkin lymphomas and related lymphomas. THRLBCL and BCLu-DLBCL\/cHL appear to have a mechanism for the regulation of EZH2 expression that is similar to NLPHL and cHL and different from that of ABCLs. In addition, EZH2 and associated signaling cascades may serve as therapeutic targets for the treatment of Hodgkin lymphomas and related lymphomas.<\/jats:p>","DOI":"10.1097\/pas.0000000000001180","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T23:17:56Z","timestamp":1540595876000},"page":"102-109","source":"Crossref","is-referenced-by-count":14,"title":["Utility of Combined EZH2, p-ERK1\/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas"],"prefix":"10.1097","volume":"43","author":[{"given":"Xuejun","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"},{"name":"Department of Hematopathology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Dorfman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrm2763","article-title":"Mechanisms of polycomb gene silencing: knowns and unknowns","volume":"10","author":"Simon","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.18632\/oncotarget.6612","article-title":"Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.18632\/oncotarget.6198","article-title":"EZH2 in normal hematopoiesis and hematological malignancies","volume":"7","author":"Herviou","year":"2015","journal-title":"Oncotarget"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3109\/10428194.2014.968780","article-title":"Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and p-STAT3 expression in a subset of cases","volume":"56","author":"Shi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2016.114","article-title":"Differential expression of Enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1\/2 and MYC in aggressive B-cell lymphomas","volume":"29","author":"Tian","year":"2016","journal-title":"Mod Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/modpathol.2017.174","article-title":"Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1\/2-related, but not MYC- or p-STAT3-related cell signaling","volume":"31","author":"Tian","year":"2018","journal-title":"Mod Pathol"},{"issue":"suppl 6","key":"R7-20230922","doi-asserted-by":"crossref","first-page":"S1057","DOI":"10.21037\/tcr.2016.11.18","article-title":"New insights into the mechanisms of EZH2\u2019s promotion of oncogenesis","volume":"5","author":"Dorfman","year":"2016","journal-title":"Transl Cancer Res"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.febslet.2012.07.066","article-title":"A687V EZH2 is a gain-of-function mutation found in lymphoma patients","volume":"586","author":"Majer","year":"2012","journal-title":"FEBS Lett"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Poc Natl Acad Sci USA"},{"key":"R13-20230922","first-page":"1329","article-title":"Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B-cell lymphoma cell growth","volume":"20","author":"Garapaty-Rao","year":"2013","journal-title":"Cell Chem Biol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","article-title":"Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms","volume":"119","author":"Score","year":"2012","journal-title":"Blood"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1128\/MCB.00162-07","article-title":"Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells","volume":"27","author":"Shi","year":"2007","journal-title":"Mol Cell Biol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","article-title":"Context-specific regulation of NF-\u03baB target gene expression by EZH2 in breast cancers","volume":"43","author":"Lee","year":"2011","journal-title":"Mol Cell"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood.V93.8.2679","article-title":"Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells","volume":"93","author":"Brauninger","year":"1999","journal-title":"Blood"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"e78812","DOI":"10.1371\/journal.pone.0078812","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma and T cell\/histiocyte rich large B-cell lymphoma\u2014endpoints of a spectrum of one disease?","volume":"8","author":"Hartmann","year":"2013","journal-title":"PLoS ONE"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"17324","DOI":"10.1074\/jbc.M800224200","article-title":"Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation","volume":"283","author":"Fujii","year":"2008","journal-title":"J Biol Chem"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/onc.2011.118","article-title":"MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes","volume":"30","author":"Fujii","year":"2011","journal-title":"Oncogene"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"669","DOI":"10.18632\/oncotarget.327","article-title":"Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms","volume":"2","author":"Koh","year":"2011","journal-title":"Oncotarget"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/hep.26720","article-title":"c-Myc mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma","volume":"59","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2008-03-147645","article-title":"MYC stimulates EZH2 expression by repression of its negative regulator miR-26a","volume":"112","author":"Sander","year":"2008","journal-title":"Blood"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1593\/neo.07971","article-title":"Inhibition of JAK1, 2\/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells","volume":"10","author":"Xiong","year":"2008","journal-title":"Neoplasia"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/path.4179","article-title":"Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer","volume":"230","author":"Lin","year":"2013","journal-title":"J Pathol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/nyas.12356","article-title":"Targeting epigenetic regulators for cancer therapy","volume":"1309","author":"Wee","year":"2014","journal-title":"Ann NY Acad Sci"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201901000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:44:39Z","timestamp":1695422679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201901000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001180","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}